Back to Newsroom

Corbus Pharmaceuticals Reports 2017 Second Quarter Financial Results and Provides Business Update

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today its financial results for the second quarter ended June 30, 2017.
READ MORE…